Aim - To assess whether interferon alpha might prevent non-A, non-B hepatitis from becoming chronic. Patients and methods - 45 patients (38 suffering from HCV infection and 7 from non-A, non-B and non-C hepatitis) were randomized for treatment with 3MU of recombinant interferon alpha-2b, three times a week for 12 weeks (26 patients - 22 with HCV): 19 (16 with HCV) were not. Biochemical and virological parameters were monitored at regular intervals for an observation period of 13 months. Results - At the end of 3 months of treatment, 16 (73%) of the patients with hepatitis C and 7 (44%) of the control group had normal serum ALT activity (p = NS), whereas 53% of the treated patients and none of the untreated group had normal ALT levels and no HCV-RNA (p = 0.0087). At the end of the 18-month follow-up, 13 (59%) treated patients and 6 (37%) of the control group had normal ALT levels (NS). 39% had normal ALT and no HCV RNA, compared with none of the controls (p = 0.035). All 7 patients with non-A, non-B, non-C hepatitis, treated and untreated, recovered uneventfully from hepatitis. Conclusions - Short term treatment with interferon alpha was effective in most patients with acute hepatitis C and led to complete recovery from hepatitis in 39% of the cases.
|Translated title of the contribution||Treatment of acute post-transfusional non-A, non-B hepatitis with recombinant interferon α-2b. A multicenter randomized controlled trial|
|Number of pages||5|
|Journal||Argomenti di Gastroenterologia Clinica|
|Publication status||Published - 1994|
ASJC Scopus subject areas